Show simple item record

Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia

dc.contributor.authorClinton, Sarah M.en_US
dc.contributor.authorHaroutunian, Vahramen_US
dc.contributor.authorMeador-Woodruff, James H.en_US
dc.date.accessioned2010-04-01T15:29:19Z
dc.date.available2010-04-01T15:29:19Z
dc.date.issued2006-08en_US
dc.identifier.citationClinton, Sarah M.; Haroutunian, Vahram; Meador-Woodruff, James H. (2006). "Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia." Journal of Neurochemistry 98(4): 1114-1125. <http://hdl.handle.net/2027.42/65970>en_US
dc.identifier.issn0022-3042en_US
dc.identifier.issn1471-4159en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/65970
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16762023&dopt=citationen_US
dc.description.abstractNumerous studies have described structural and functional abnormalities of the thalamus in schizophrenia, but surprisingly few studies have examined neurochemical abnormalities that accompany these pathological changes. We previously identified abnormalities of multiple molecules associated with glutamatergic neurotransmission, including changes in NMDA receptor subunit transcripts and binding sites and NMDA receptor-associated post-synaptic density (PSD) protein transcripts in the thalamus of elderly patients with schizophrenia. In the present study, we performed western blot analysis to determine whether protein levels of NMDA receptor subunits (NR1, NR2A, NR2B) and associated PSD proteins (NF-L, PSD95, SAP102) are altered in schizophrenia. Thalamic tissue from each subject was grossly dissected into two regions: a dorsomedial region containing limbic-associated dorsomedial, anterior and central medial thalamic nuclei; and a ventral thalamus region that primarily consisted of the ventral lateral nucleus. We observed increased protein expression of the NR2B NMDA receptor subunit and its associated intracellular protein, PSD95, in the dorsomedial thalamus of patients with schizophrenia, but the other molecules were unchanged, and we found no changes in the ventral thalamus. These data provide additional evidence of thalamic neurochemical abnormalities, particularly in thalamic nuclei which project to limbic regions of the brain. Further, these findings provide additional evidence of NMDA receptor alterations in schizophrenia, which may play an important role in the neurobiology of the illness.en_US
dc.format.extent299839 bytes
dc.format.extent3110 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2006 The Authors Journal Compilation 2006 International Society for Neurochemistryen_US
dc.subject.otherGlutamateen_US
dc.subject.otherMediodorsal Nucleusen_US
dc.subject.otherNMDA Receptor Subunit 2Ben_US
dc.subject.otherPost-synaptic Density Protein 95en_US
dc.titleUp-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophreniaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Molecular and Behavioral Neuroscience Institute and Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationother† Department of Psychiatry, Mount Sinai School of Medicine, New York, USAen_US
dc.identifier.pmid16762023en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/65970/1/j.1471-4159.2006.03954.x.pdf
dc.identifier.doi10.1111/j.1471-4159.2006.03954.xen_US
dc.identifier.sourceJournal of Neurochemistryen_US
dc.identifier.citedreferenceAndreasen N. C., Ehrhardt J. C., Swayze V. W., 2nd, Alliger R. J., Yuh W. T., Cohen G. and Ziebell S. ( 1990 ) Magnetic resonance imaging of the brain in schizophrenia: the pathophysiologic significance of structural abnormalities. Arch. Gen. Psychiatry 47, 35 – 44.en_US
dc.identifier.citedreferenceAndreasen N. C., Arndt S., Swayze V., 2nd, Cizadlo T., Flaum M., O'Leary D., Ehrhardt J. C. and Yuh W. T. ( 1994 ) Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266, 294 – 298.en_US
dc.identifier.citedreferenceAndreasen N. C., O'Leary D. S., Cizadlo T., Arndt S., Rezai K., Ponto L. L., Watkins G. L. and Hichwa R. D. ( 1996 ) Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry. Proc. Natl Acad. Sci. USA 93, 9985 – 9990.en_US
dc.identifier.citedreferenceBarria A. and Malinow R. ( 2002 ) Subunit-specific NMDA receptor trafficking to synapses. Neuron 35, 345 – 353.en_US
dc.identifier.citedreferenceBraus D. F., Weber-Fahr W., Tost H., Ruf M. and Henn F. A. ( 2002 ) Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study. Arch. Gen. Psychiatry 59, 696 – 701.en_US
dc.identifier.citedreferenceBuchsbaum M. S. and Hazlett E. A. ( 1998 ) Positron emission tomography studies of abnormal glucose metabolism In schizophrenia. Schizophrenia Bull. 24, 343 – 364.en_US
dc.identifier.citedreferenceBuchsbaum M. S., Someya T., Teng C. Y., Abel L., Chin S., Najafi A., Haier R. J., Wu J. and Bunney W. E., Jr ( 1996 ) PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am. J. Psychiatry 153, 191 – 199.en_US
dc.identifier.citedreferenceButler P. D., Zemon V., Schechter I., Saperstein A. M., Hoptman M. J., Lim K. O., Revheim N., Silipo G. and Javitt D. C. ( 2005 ) Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch. Gen. Psychiatry 62, 495 – 504.en_US
dc.identifier.citedreferenceByne W., Buchsbaum M. S., Kemether E., Hazlett E. A., Shinwari A., Mitropoulou V. and Siever L. J. ( 2001 ) Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch. Gen. Psychiatry 58, 133 – 140.en_US
dc.identifier.citedreferenceByne W., Buchsbaum M. S., Mattiace L. A., Hazlett E. A., Kemether E., Elhakem S. L., Purohit D. P., Haroutunian V. and Jones L. ( 2002 ) Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am. J. Psychiatry 159, 59 – 65.en_US
dc.identifier.citedreferenceCarroll R. C. and Zukin R. S. ( 2002 ) NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity. Trends Neurosci. 25, 571 – 577.en_US
dc.identifier.citedreferenceClinton S. M. and Meador-Woodruff J. H. ( 2004a ) Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophrenia Res. 69, 237 – 253.en_US
dc.identifier.citedreferenceClinton S. M. and Meador-Woodruff J. H. ( 2004b ) Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 29, 1353 – 1362.en_US
dc.identifier.citedreferenceClinton S. M., Haroutunian V., Davis K. L. and Meador-Woodruff J. H. ( 2003 ) Altered expression of NMDA receptor-associated post-synaptic density proteins in the thalamus in schizophrenia. Am. J. Psychiatry 160, 1100 – 1109.en_US
dc.identifier.citedreferenceClinton S. M., Abelson S., Haroutunian V., Davis K. L. and Meador-Woodruff J. H. ( 2004 ) Neurofilament subunit protein abnormalities in the thalamus in schizophrenia. Thalamus & Related Syst. 2, 265 – 272.en_US
dc.identifier.citedreferenceClinton S. M., Ibrahim H., Frey K. A., Davis K. L., Haroutunian V. and Meador-Woodruff J. H. ( 2005 ) Dopaminergic abnormalities in the thalamus in schizophrenia involve the intracellular signal integrating proteins calcyon and spinophilin. Am. J. Psychiatry 162, 1859 – 1871.en_US
dc.identifier.citedreferenceCohen B. and Wan W. ( 1996 ) The thalamus as a site of action of antipsychotic drugs. Am. J. Psychiatry 153, 104 – 106.en_US
dc.identifier.citedreferenceCohen B. M. and Yurgelun-Todd D. ( 2001 ) Alterations of thalamic activity in schizophrenia and in response to antipsychotic drugs. Neuropsychopharmacology 25, 305 – 312.en_US
dc.identifier.citedreferenceCullen T. J., Walker M. A., Parkinson N., Craven R., Crow T. J., Esiri M. M. and Harrison P. J. ( 2003 ) A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophrenia Res. 60, 157 – 166.en_US
dc.identifier.citedreferenceDanos P., Baumann B., Bernstein H. G., Franz M., Stauch R., Northoff G., Krell D., Falkai P. and Bogerts B. ( 1998 ) Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res. 82, 1 – 10.en_US
dc.identifier.citedreferenceDanos P., Baumann B., Bernstein H. G., Stauch R., Krell D., Falkai P. and Bogerts B. ( 2002 ) The ventral lateral posterior nucleus of the thalamus in schizophrenia: a post-mortem study. Psychiatry Res. 114, 1 – 9.en_US
dc.identifier.citedreferenceDanos P., Baumann B., Kramer A., Bernstein H. G., Stauch R., Krell D., Falkai P. and Bogerts B. ( 2003 ) Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophrenia Res. 60, 141 – 155.en_US
dc.identifier.citedreferenceDasari M., Friedman L., Jesberger J., Stuve T. A., Findling R. L., Swales T. P. and Schulz S. C. ( 1999 ) A magnetic resonance imaging study of thalamic area in adolescent patients with either schizophrenia or bipolar disorder as compared to healthy controls. Psychiatry Res. 91, 155 – 162.en_US
dc.identifier.citedreferenceDean B., Scarr E., Bradbury R. and Copolov D. ( 1999 ) Decreased hippocampal (CA3) NMDA receptors in schizophrenia. Synapse 32, 67 – 69.en_US
dc.identifier.citedreferenceDeutch A., Ongur D. and Duman R. ( 1995 ) Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel antipsychotic drug action. Neuroscience 66, 337 – 346.en_US
dc.identifier.citedreferenceDomino E. and Luby E. ( 1981 ) Abnormal mental states induced by phencyclidine as a model of schizophrenia, in PCP (Phencyclidine): Historical and Current Perspectives ( Domino E., ed.), pp. 401 – 418. NPP Books, Ann. Arbor, MI.en_US
dc.identifier.citedreferenceDorph-Petersen K. A., Pierri J. N., Sun Z., Sampson A. R. and Lewis D. A. ( 2004 ) Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. J. Comp. Neurol. 472, 449 – 462.en_US
dc.identifier.citedreferenceDracheva S., Marras S. A., Elhakem S. L., Kramer F. R., Davis K. L. and Haroutunian V. ( 2001 ) N -methyl-d-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 158, 1400 – 1410.en_US
dc.identifier.citedreferenceEhlers M., Fung E., O'Brien R. and Huganir R. ( 1998 ) Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J. Neurosci. 18, 720 – 730.en_US
dc.identifier.citedreferenceEmamian E. S., Karayiorgou M. and Gogos J. A. ( 2004 ) Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. J. Neurosci. 24, 1561 – 1564.en_US
dc.identifier.citedreferenceEttinger U., Chitnis X. A., Kumari V., Fannon D. G., Sumich A. L., O'Ceallaigh S., Doku V. C. and Sharma T. ( 2001 ) Magnetic resonance imaging of the thalamus in first-episode psychosis. Am. J. Psychiatry 158, 116 – 118.en_US
dc.identifier.citedreferenceFlaum M., Swayze V. W., 2nd, O'Leary D. S., Yuh W. T., Ehrhardt J. C., Arndt S. V. and Andreasen N. C. ( 1995 ) Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia. Am. J. Psychiatry 152, 704 – 714.en_US
dc.identifier.citedreferenceFukaya M., Kato A., Lovett C., Tonegawa S. and Watanabe M. ( 2003 ) Retention of NMDA receptor NR2 subunits in the lumen of endoplasmic reticulum in targeted NR1 knockout mice. Proc. Natl Acad. Sci. USA 100, 4855 – 4860.en_US
dc.identifier.citedreferenceGao X. M., Sakai K., Roberts R. C., Conley R. R., Dean B. and Tamminga C. A. ( 2000 ) Ionotropic glutamate receptors and expression of N -methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 157, 1141 – 1149.en_US
dc.identifier.citedreferenceGilbert A. R., Rosenberg D. R., Harenski K., Spencer S., Sweeney J. A. and Keshavan M. S. ( 2001 ) Thalamic volumes in patients with first-episode schizophrenia. Am. J. Psychiatry 158, 618 – 624.en_US
dc.identifier.citedreferenceGoff D. C. and Coyle J. T. ( 2001 ) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158, 1367 – 1377.en_US
dc.identifier.citedreferenceGoff D. C., Tsai G., Manoach D. S. and Coyle J. T. ( 1995 ) Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 152, 1213 – 1215.en_US
dc.identifier.citedreferenceGrimwood S., Slater P., Deakin J. F. W. and Hutson P. H. ( 1999 ) NR2B-containing NMDA receptors are upregulated in temporal cortex in schizophrenia. Neuroreport 10, 461 – 465.en_US
dc.identifier.citedreferenceGuillaud L., Setou M. and Hirokawa N. ( 2003 ) KIF17 dynamics and regulation of NR2B trafficking in hippocampal neurons. J. Neurosci. 23, 131 – 140.en_US
dc.identifier.citedreferenceGur R. E., Maany V., Mozley P. D., Swanson C., Bilker W. and Gur R. C. ( 1998 ) Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry 155, 1711 – 1717.en_US
dc.identifier.citedreferenceHarrison P. J. and Weinberger D. R. ( 2005 ) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10, 40 – 68 ; image 45.en_US
dc.identifier.citedreferenceHazlett E. A., Buchsbaum M. S., Byne W., Wei T. C., Spiegel-Cohen J., Geneve C., Kinderlehrer R., Haznedar M. M., Shihabuddin L. and Siever L. J. ( 1999 ) Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am. J. Psychiatry 156, 1190 – 1199.en_US
dc.identifier.citedreferenceHeckers S., Rauch S. L., Goff D., Savage C. R., Schacter D. L., Fischman A. J. and Alpert N. M. ( 1998 ) Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat. Neurosci. 1, 318 – 323.en_US
dc.identifier.citedreferenceHirai T. and Jones E. G. ( 1989 ) A new parcellation of the human thalamus on the basis of histochemical staining. Brain Res. Brain Res. Rev. 14, 1 – 34.en_US
dc.identifier.citedreferenceHolcomb H., Cascella N., Thaker G., Medoff D., Dannals R. and Tamminga C. ( 1996 ) Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry 153, 41 – 49.en_US
dc.identifier.citedreferenceHollmann M. and Heinemann S. ( 1994 ) Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31 – 108.en_US
dc.identifier.citedreferenceIbrahim H. M., Hogg A. J., Healy D. J., Haroutunian V., Davis K. L. and Meador-Woodruff J. H. ( 2000 ) Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am. J. Psychiatry 157, 1811 – 1823.en_US
dc.identifier.citedreferenceJavitt D. C. ( 2004 ) Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 9, 979.en_US
dc.identifier.citedreferenceJavitt D., Zylberman I., Zukin S., Heresco-Levy U. and Lindenmayer J. ( 1994 ) Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151, 1234 – 1336.en_US
dc.identifier.citedreferenceJones E. G. ( 1998 ) The thalamus of primates, in The Primate Nervous System, Part II, Vol. 14 ( Bloom F. E., Bjorklund A. and Hokfelt T., eds), pp. 1 – 246. Elsevier, New York.en_US
dc.identifier.citedreferenceKiehl K. A., Stevens M. C., Celone K., Kurtz M. and Krystal J. H. ( 2005 ) Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol. Psychiatry 57, 1029 – 1040.en_US
dc.identifier.citedreferenceKoh P. O., Bergson C., Undie A. S., Goldman-Rakic P. S. and Lidow M. S. ( 2003 ) Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Arch. Gen. Psychiatry 60, 311 – 319.en_US
dc.identifier.citedreferenceKonick L. C. and Friedman L. ( 2001 ) Meta-analysis of thalamic size in schizophrenia. Biol. Psychiatry 49, 28 – 38.en_US
dc.identifier.citedreferenceKrystal J. H., D'Souza D. C., Petrakis I. L., Belger A., Berman R. M., Charney D. S., Abi-Saab W. and Madonick S. ( 1999 ) NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Rev. Psychiatry 7, 125 – 143.en_US
dc.identifier.citedreferenceLahti A., Holcomb H., Medoff D. and Tamminga C. ( 1995 ) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6, 869 – 872.en_US
dc.identifier.citedreferenceLau L., Mammen A., Ehlers M., Kindler S., Chung W., Garner C. and Huganir R. ( 1996 ) Interaction of the N -methyl-d-aspartate receptor complex with a novel synapse-associated protein, SAP102. J. Biol. Chem. 271, 21 622 – 21 628.en_US
dc.identifier.citedreferenceLezcano N., Mrzljak L., Eubanks S., Levenson R., Goldman-Rakic P. and Bergson C. ( 2000 ) Dual signaling regulated by calcyon, a D1 dopamine receptor interacting protein. Science 287, 1660 – 1664.en_US
dc.identifier.citedreferenceLidow M. S., Roberts A., Zhang L., Koh P. O., Lezcano N. and Bergson C. ( 2001 ) Receptor crosstalk protein, calcyon, regulates affinity state of dopamine D1 receptors. Eur. J. Pharmacol. 427, 187 – 193.en_US
dc.identifier.citedreferenceLinden A. M., Vasanen J., Storvik M., Lakso M., Korpi E. R., Wong G. and Castren E. ( 2001 ) Uncompetitive antagonists of the N -methyl-d-aspartate (NMDA) receptors alter the mRNA expression of proteins associated with the NMDA receptor complex. Pharmacol. Toxicol. 88, 98 – 105.en_US
dc.identifier.citedreferenceMai J., Assheuer J. and Paxinos G. ( 1997 ) Atlas of the Human Brain. Academic Press, San Diego.en_US
dc.identifier.citedreferenceMcIlhinney R. A., Le Bourdelles B., Molnar E., Tricaud N., Streit P. and Whiting P. J. ( 1998 ) Assembly intracellular targeting and cell surface expression of the human N -methyl-d-aspartate receptor subunits NR1a and NR2A in transfected cells. Neuropharmacology 37, 1355 – 1367.en_US
dc.identifier.citedreferenceMueller H. T. and Meador-Woodruff J. H. ( 2004 ) NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophrenia Res. 71, 361 – 370.en_US
dc.identifier.citedreferenceMueller H. T., Haroutunian V., Davis K. L. and Meador-Woodruff J. H. ( 2004 ) Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Mol. Brain Res. 121 ( 1–2 ), 60 – 69.en_US
dc.identifier.citedreferenceMuller B., Kistner U., Kindler S. et al. ( 1996 ) SAP102, a novel postsynaptic protein that interacts with NMDA receptor complexes in vivo. Neuron 17, 255 – 265.en_US
dc.identifier.citedreferenceNudmamud-Thanoi S. and Reynolds G. P. ( 2004 ) The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neuroscience Lett. 372, 173 – 177.en_US
dc.identifier.citedreferencePakkenberg B. ( 1990 ) Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch. Gen. Psychiatry 47, 1023 – 1028.en_US
dc.identifier.citedreferencePakkenberg B. ( 1992 ) The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics. Schizophrenia Res. 7, 95 – 100.en_US
dc.identifier.citedreferencePakkenberg B. ( 1993 ) Leucotomized schizophrenics lose neurons in the mediodorsal thalamic nucleus. Neuropathol. Appl. Neurobiol. 19, 373 – 380.en_US
dc.identifier.citedreferencePopken G. J., Bunney W. E., Jr, Potkin S. G. and Jones E. G. ( 2000 ) Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc. Natl Acad. Sci. USA 97, 9276 – 9280.en_US
dc.identifier.citedreferenceResnick S. M., Gur R. E., Alavi A., Gur R. C. and Reivich M. ( 1988 ) Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Res. 24, 1 – 11.en_US
dc.identifier.citedreferenceRichardson-Burns S. M., Haroutunian V., Davis K. L., Watson S. J. and Meador-Woodruff J. H. ( 2000 ) Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol. Psychiatry 47, 22 – 28.en_US
dc.identifier.citedreferenceRutter A. and Stephenson F. ( 2000 ) Coexpression of postsynaptic density-95 protein with NMDA receptors results in enhanced receptor expression together with a decreased sensitivity to l-glutamate. J. Neurochem. 75, 2501 – 2510.en_US
dc.identifier.citedreferenceSans N., Prybylowski K., Petralia R. S., Chang K., Wang Y. X., Racca C., Vicini S. and Wenthold R. J. ( 2003 ) NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex. Nat. Cell Biol. 5, 520 – 530.en_US
dc.identifier.citedreferenceScott D. B., Blanpied T. A., Swanson G. T., Zhang C. and Ehlers M. D. ( 2001 ) An NMDA receptor ER retention signal regulated by phosphorylation and alternative splicing. J. Neurosci. 21, 3063 – 3072.en_US
dc.identifier.citedreferenceSetou M., Nakagawa T., Seog D. H. and Hirokawa N. ( 2000 ) Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. Science 288, 1796 – 1802.en_US
dc.identifier.citedreferenceSheng M. H. -T. ( 2001 ) The postsynaptic specialization, in Synapses ( Cowan W. M., Sudhof T. C. and Stevens C. F., eds), pp. 315 – 355. The Johns Hopkins University Press, Baltimore.en_US
dc.identifier.citedreferenceSheng M. and Pak D. ( 2000 ) Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. Annu. Rev. Physiol. 62, 755 – 778.en_US
dc.identifier.citedreferenceSilbersweig D. A., Stern E., Frith C. et al. ( 1995 ) A functional neuroanatomy of hallucinations in schizophrenia. Nature 378, 176 – 179.en_US
dc.identifier.citedreferenceSmith R. E., Haroutunian V., Davis K. L. and Meador-Woodruff J. H. ( 2001a ) Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport 12, 2885 – 2887.en_US
dc.identifier.citedreferenceSmith R. E., Haroutunian V., Davis K. L. and Meador-Woodruff J. H. ( 2001b ) Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am. J. Psychiatry 158, 1393 – 1399.en_US
dc.identifier.citedreferenceStaal W. G., Hulshoff Pol H. E., Schnack H., van der Schot A. C. and Kahn R. S. ( 1998 ) Partial volume decrease of the thalamus in relatives of patients with schizophrenia. Am. J. Psychiatry 155, 1784 – 1786.en_US
dc.identifier.citedreferenceStandley S., Roche K. W., McCallum J., Sans N. and Wenthold R. J. ( 2000 ) PDZ domain suppression of an ER retention signal in NMDA receptor NR1 splice variants. Neuron 28, 887 – 898.en_US
dc.identifier.citedreferenceSteigerwald F., Schulz T. W., Schenker L. T., Kennedy M. B., Seeburg P. H. and Kohr G. ( 2000 ) C-Terminal truncation of NR2A subunits impairs synaptic but not extrasynaptic localization of NMDA receptors. J. Neurosci. 20, 4573 – 4581.en_US
dc.identifier.citedreferenceSteriade M., Jones E. G. and McCormick D. A. ( 1997 ) Thalamus: Organization and Function, Vol. 1. Elsevier, Amsterdam.en_US
dc.identifier.citedreferenceSymond M. P., Harris A. W., Gordon E. and Williams L. M. ( 2005 ) ‘Gamma synchrony’ in first-episode schizophrenia: a disorder of temporal connectivity? Am. J. Psychiatry 162, 459 – 465.en_US
dc.identifier.citedreferenceTakahashi H., Koeda M., Oda K., Matsuda T., Matsushima E., Matsuura M., Asai K. and Okubo Y. ( 2004 ) An fMRI study of differential neural response to affective pictures in schizophrenia. Neuroimage 22, 1247 – 1254.en_US
dc.identifier.citedreferenceTamminga C. A., Thaker G. K., Buchanan R., Kirkpatrick B., Alphs L. D., Chase T. N. and Carpenter W. T. ( 1992 ) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry 49, 522 – 530.en_US
dc.identifier.citedreferenceToro C. and Deakin J. F. ( 2005 ) NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophrenia Res. 80, 323 – 330.en_US
dc.identifier.citedreferenceToyooka K., Iritani S., Makifuchi T. et al. ( 2002 ) Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J. Neurochem. 83, 797 – 806.en_US
dc.identifier.citedreferenceTsai G., Yang P., Chung L. C., Lange N. and Coyle J. T. ( 1998 ) d-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44, 1081 – 1089.en_US
dc.identifier.citedreferenceUlas J., Nguyen L. and Cotman C. W. ( 1993 ) Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuroreport 4, 1049 – 1051.en_US
dc.identifier.citedreferenceVita A., Bressi S., Perani D., Invernizzi G., Giobbio G. M., Dieci M., Garbarini M., Del Sole A. and Fazio F. ( 1995 ) High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. Am. J. Psychiatry 152, 876 – 882.en_US
dc.identifier.citedreferenceWashbourne P., Liu X. B., Jones E. G. and McAllister A. K. ( 2004 ) Cycling of NMDA receptors during trafficking in neurons before synapse formation. J. Neurosci. 24, 8253 – 8264.en_US
dc.identifier.citedreferenceWyneken U., Smalla K. H., Marengo J. J. et al. ( 2001 ) Kainate-induced seizures alter protein composition and N -methyl-d-aspartate receptor function of rat forebrain postsynaptic densities. Neuroscience 102, 65 – 74.en_US
dc.identifier.citedreferenceYoung K., Manaye K., Liang C., Hicks P. and German D. ( 2000 ) Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol. Psychiatry 47, 944 – 953.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.